MRK Looks 21.6% Overvalued on GF Value™ Amid Dividend Sustainabi

Merck (MRK) announced that its KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) has been approved in Japan for subcutaneous use. The approval covers all KEYTRUDA indications. KEYTRUDA QLEX can be administered in one minute, offering convenience. The approval is based on a Phase 3 trial showing comparable efficacy to KEYTRUDA. KEYTRUDA QLEX is also approved in the U.S. and Europe.

Merck (MRK) awaits FDA decision on Winrevair for pulmonary arterial hypertension. Mirum (MIRM) faces decision on Zilurgisertib for FOP, with Incyte (INCY) holding economic interest. Grail (GRAL) has FDA advisory committee review for Galleri multi-cancer blood test. MRK up 40%, INCY up 23%, MIRM up 17.6%, GRAL down 9%.

Merck (MRK) stock rose 87% in the past year, despite revenue growth of 4.6% to $66.6B. The increase is attributed to investor optimism about future drugs, including the acquisition of Terns Pharmaceuticals for $5.7B. Merck's pipeline showed progress with FDA approvals and positive trial results, but KEYTRUDA's patent expiration in 2028 poses a risk. The company raised its 2026 revenue guidance to $66.3B-$67.3B, indicating a slight deceleration.

Merck & Co. (NYSE: MRK) received a positive recommendation from a European regulatory committee for its cancer therapy Keytruda in combination with Padcev to treat adults with resectable muscle-invasive bladder cancer. The recommendation is based on Phase 3 KEYNOTE-B15 study data, which showed a 47% reduction in event-free survival events and a 35% reduction in the risk of death compared to standard chemotherapy. The European Commission is expected to make a final decision by Q4 2026. Merck shar

Merck (MRK) announced the EU's CHMP recommended approval of KEYTRUDA plus Padcev for resectable muscle-invasive bladder cancer, based on Phase 3 trial results. The combination showed improvements in event-free survival, overall survival, and pathologic complete response. The European Commission's decision is expected by Q4 2026. MRK shares were down 0.24% in pre-market trading.

Merck & Co (MRK) received a favorable opinion from the European Medicines Agency for Keytruda's use in bladder cancer treatment. The company offers a 2.3% dividend yield but has a high payout ratio of 1.05, raising sustainability concerns. MRK's stock is overvalued by 22.5% according to GF Value™, with a GF Score™ of 78/100. Insider selling and a high P/E ratio of 117.63x add to investor caution.